Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
COCP 
Cocrystal Pharma Inc (COCP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/03/2025: COCP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8
1 Year Target Price $8
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.84% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.21M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 2 | Beta 2.24 | 52 Weeks Range 1.01 - 3.26 | Updated Date 11/3/2025 |
52 Weeks Range 1.01 - 3.26 | Updated Date 11/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.87% | Return on Equity (TTM) -110.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12800004 | Price to Sales(TTM) 92.45 |
Enterprise Value 12800004 | Price to Sales(TTM) 92.45 | ||
Enterprise Value to Revenue 17.89 | Enterprise Value to EBITDA 0.66 | Shares Outstanding 13039348 | Shares Floating 6770749 |
Shares Outstanding 13039348 | Shares Floating 6770749 | ||
Percent Insiders 34.18 | Percent Institutions 5.27 |
Upturn AI SWOT
Cocrystal Pharma Inc
Company Overview
History and Background
Cocrystal Pharma Inc. was founded in 2007. The company focuses on developing novel antiviral therapeutics. It initially focused on creating new chemical entities by creating new crystalline forms of existing drugs and has since shifted more towards novel antiviral candidates.
Core Business Areas
- Antiviral Drug Development: Focuses on discovering and developing new antiviral therapies to treat various viral diseases, including influenza, coronaviruses, noroviruses, and hepatitis C.
Leadership and Structure
Dr. James Martin Freeman serves as the Chairman of the Board and CEO. The company is structured with a research and development team and a management team.
Top Products and Market Share
Key Offerings
- CC-42344: A protease inhibitor for influenza A, currently in clinical development. Market share data is not publicly available as it is not yet approved. Competitors include Roche (Tamiflu) and BioCryst Pharmaceuticals (Rapivab).
- CC-31244: An oral replication inhibitor for coronaviruses, including SARS-CoV-2, currently in preclinical development. Market share data is not applicable at this stage. Competitors are Pfizer (Paxlovid) and Gilead Sciences (Veklury).
Market Dynamics
Industry Overview
The antiviral drug market is experiencing growth due to increasing prevalence of viral infections, growing awareness, and technological advancements in drug development.
Positioning
Cocrystal Pharma is a smaller player in the antiviral market, focusing on niche areas with unmet medical needs. Their competitive advantage lies in their novel drug candidates and cocrystal technology.
Total Addressable Market (TAM)
The global antiviral drug market is estimated to reach hundreds of billions of dollars. Cocrystal Pharma's positioning targets specific viral infections with the potential to capture a portion of this market upon successful drug development and approval.
Upturn SWOT Analysis
Strengths
- Novel antiviral drug candidates
- Cocrystal technology for drug optimization
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Small market capitalization
Opportunities
- Partnerships with larger pharmaceutical companies
- FDA fast-track designation for promising drug candidates
- Expansion into new antiviral targets
Threats
- Failure in clinical trials
- Competition from established pharmaceutical companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- Roche (ROG.SW)
- Gilead Sciences (GILD)
- Pfizer (PFE)
- BioCryst Pharmaceuticals (BCRX)
Competitive Landscape
Cocrystal Pharma faces intense competition from larger, more established pharmaceutical companies. Its advantages lie in its innovative technology and targeted approach, but it needs to overcome financial constraints.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company being in the development stage with no approved products.
Future Projections: Future growth depends on the successful development and commercialization of its antiviral drug candidates. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing CC-42344 and CC-31244 through clinical and preclinical development.
Summary
Cocrystal Pharma is a development-stage biopharmaceutical company with promising antiviral drug candidates. Its success hinges on the outcomes of its clinical trials and its ability to secure partnerships. The company faces significant financial risks and competition from larger players. While innovative, financial constraints need to be monitored.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data is estimated and may not be precise. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cocrystal Pharma Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 2011-05-19 | Co-Founder, Co-CEO & President Dr. Sam Lee Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://www.cocrystalpharma.com |
Full time employees 11 | Website https://www.cocrystalpharma.com | ||
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.